The DOI matches its Crossref record; 82 of the 95 references it cites were found in a registry or an index.
Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray
Open accessAbstract
A multistep model for pancreatic adenocarcinoma has been proposed recently. In this model, well-defined, noninvasive ductal lesions are recognized as precursors of invasive cancer and have been classified under the nomenclature of pancreatic intraepithelial neoplasia, or PanIN. Increasing evidence suggests that PanINs represent true neoplasms of the pancreatic ductal epithelium, accumulating histologic and genetic abnormalities in their progression toward invasive cancer. We have constructed a tissue microarray containing 55 PanIN lesions of all histologic grades in order to perform a multicomponent analysis of the pancreatic adenocarcinoma progression model. The protein products of 14 genes encompassing a variety of functional classes, such as tumor suppressor genes (p53, Smad4/Dpc4), oncogenes (beta-catenin), cell cycle antigens (p16, cyclin D1), proliferation antigens (Ki-67, topoisomerase II alpha), and epithelial apomucins (MUC1, MUC2, MUC5), as well as "novel" genes described as differentially up-regulated in invasive pancreas cancer by global microarray expression analysis (mesothelin, prostate stem cell antigen, fascin, and 14-3-3varsigma), were analyzed by immunohistochemistry on the PanIN tissue microarray. Comparison of the results from the current study with previously published data performed on routine histologic sections of PanINs demonstrates that tissue microarrays are a valid platform for molecular analysis not only of invasive cancers but of precursor lesions as well. In addition, this study demonstrates that molecular abnormalities in PanINs are not random but can usually be stratified into "early" changes (e.g., expression of MUC5 and prostate stem antigen, or loss of p16), "intermediate" changes (e.g., expression of cyclin D1), and "late" changes (e.g., expression of p53, proliferation antigens, MUC1, mesothelin, and 14-3-3varsigma, or loss of Smad4/Dpc4). Understanding the molecular pathogenesis of precursor lesions of invasive pancreatic adenocarcinomas using a high-throughput tissue microarray-based approach is a valuable adjunct to designing rational strategies for early detection of this lethal neoplasm.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early molecular profiling coupled with histology allowed for the development of a putative pathological progression model; analogous to the adenoma-carcinoma model in the colon23”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [23]
In the citing paper
“The temporal appearance of these alterations during multistep progression suggests that TP53 and SMAD4 typically occur late, usually in the setting of high-grade lesions or cancer in both PanINs and IPMNs23,51.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [23]
In the citing paper
“For example, approximately 40% of pancreatic ductal adenocarcinomas have mutated TP53 and deleted ARF (Heinmoller, et al., 2000; Hustinx, et al., 2005; Maitra, et al., 2003).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Maitra, et al., 2003
Citations
Cites
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. J. (2001) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,281
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Self-citationDelineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R. B., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,675
Is a p53-Regulated Inhibitor of G2/M Progression
Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1997) · Molecular Cell · doi:10.1016/s1097-2765(00)80002-7 · Cited by 1,251
Hruban, R. H., Adsay, N. V., Albores–Saavedra, J., Compton, C., Garrett, E. S., Goodman, S. N., Kern, S. E., Klimstra, D. S., Klöppel, G., Longnecker, D. S., et al. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200105000-00003 · Cited by 1,126
Self-citationSpecific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Progression model for pancreatic cancer.
Hruban, R. H., Goggins, M., Parsons, J., & Kern, S. E. (2000) · PubMed · Cited by 872
Self-citationChang, K., & Pastan, I. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 747
Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer
Reiter, R. E., Gu, Z., Watabe, T., THOMAS, G. V., Szigeti, K., Davis, E., Wahl, M. I., Nisitani, S., Yamashiro, J. M., Beau, M. M. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1735 · Cited by 675
Cited by
Sorted by citations
Items 201–300 of 425
Alvarez, H., Rojas, P. L., Yong, K., Ding, H. Y., Xu, G., Prasad, P. N., Wang, J. C. Y., Canto, M. I., Eshleman, J. R., Montgomery, E. A., et al. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.06.006 · Cited by 22
Self-citationHayashi, Y., Toda, K., Saibara, T., Okamoto, S., Osanai, M., Enzan, H., & Lee, G. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0683-8 · Cited by 22
Rougemont, A., Genevay, M., McKee, T., Gremaud, M., Mentha, G., & Rubbia‐Brandt, L. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-0899-3 · Cited by 22
Evaluation of pancreatic intraepithelial neoplasia and mucin expression in normal pancreata
Matsuyama, M., Kondo, F., Ishihara, T., Yamaguchi, T., Ito, R., Tsuyuguchi, T., Tawada, K., & Yokosuka, O. (2011) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-011-0401-x · Cited by 21
Familial intraductal papillary mucinous neoplasms of the pancreas
Rebours, V., Couvelard, A., Peyroux, J.-L., Sauvanet, A., Hammel, P. R., Ruszniewski, P. B., & Lévy, P. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2011.07.003 · Cited by 21
Yamasaki, S., Miura, Y., Davydova, J., Vickers, S. M., & Yamamoto, M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27983 · Cited by 21
Human pancreatic cancer progression: an anarchy among CCN-siblings
Banerjee, S. K., Maity, G., Haque, I., Ghosh, A., Sarkar, S., Gupta, V. G., Campbell, D. R., Hoff, D. D. V., & Banerjee, S. (2016) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0343-9 · Cited by 21
Lisovsky, M., Dresser, K., Woda, B. A., & Mino-Kenudson, M. A. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.12.004 · Cited by 20
Dorf, J., Zaręba, K. P., Guzińska-Ustymowicz, K., Kędra, B., Kemonä, A., & Pryczynicz, A. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1751-z · Cited by 20
Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
Badheeb, M. A., Abdelrahim, A., Esmail, A., Umoru, G., Abboud, K., Al-Najjar, E., Rasheed, G. O., Alkhulaifawi, M., Abudayyeh, A., & Abdelrahim, M. (2022) · Current Oncology · doi:10.3390/curroncol29110686 · Cited by 20
Omori, Y., Furukawa, T., Scarpa, A., & Luchini, C. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-209012 · Cited by 19
Pathology of Pancreatic Cancer Precursor Lesions
Noë, M., & Brosens, L. A. A. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.05.004 · Cited by 19
Das, K. K., & Early, D. S. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0149-8 · Cited by 19
Sullivan, C. A. W., & Chung, G. G. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.n.022 · Cited by 19
Malvi, D., Vasuri, F., Maloberti, T., Sanza, V., Leo, A. D., Fornelli, A., Masetti, M., Benini, C., Lombardi, R., Offi, M. F., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12051058 · Cited by 18
Coptisine suppresses proliferation and inhibits metastasis in human pancreatic cancer PANC-1 cells
Zhang, Y., Zhang, X., Miao, X., Yuan, Y.-Y., Gao, J., Li, X., Liu, Y., & Tan, P. (2019) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2019.1585820 · Cited by 18
Tissue Microarrays: Construction and Use
Remotti, H. E. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-287-2_2 · Cited by 18
Immunohistology of the Pancreas, Biliary Tract, and Liver
Baştürk, O., Farris, A. B., & Adsay, V. N. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5766-6.00019-4 · Cited by 18
Ma, J., Fu, S., Tan, J., Han, Y., Chen, Y., Deng, X., Shen, H., Zeng, S., Peng, Y., & Cai, C. (2025) · Advanced Science · doi:10.1002/advs.202502714 · Cited by 17
Screening for Pancreatic Cancer
Wada, K., Takaori, K., & Traverso, L. W. (2015) · Surgical Clinics of North America · doi:10.1016/j.suc.2015.05.010 · Cited by 17
DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines
Urbanova, M., Buociková, V., Trnkova, L., Strapcova, S., Kajabová, V. H., Barreto, E., Novisedláková, M., Tomáš, M., Dubovan, P., Earl, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042117 · Cited by 17
Hwang, I. K., Kim, H., Lee, Y. S., Kim, J., Cho, J. Y., Yoon, Y., Han, H., & Hwang, J. (2015) · Cancer Science · doi:10.1111/cas.12744 · Cited by 17
Assessing the role of the EGF receptor in the development and progression of pancreatic cancer
Moore, M. J., Cook, N., & Frese, K. K. (2014) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s58925 · Cited by 17
The secret origins and surprising fates of pancreas tumors
Bailey, J. M., DelGiorno, K. E., & Crawford, H. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu056 · Cited by 17
K-ras and Dpc4 mutations in chronic pancreatitis: case series.
Hadžija, M. P., Korolija, M., Razumović, J. J., Pavković, P., Hadžija, M., & Kapitanović, S. (2007) · PubMed Central · Cited by 17
Molecular Alterations in Exocrine Neoplasms of the Pancreas
Ranganathan, P., Gowda, H., & Pandey, A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.405 · Cited by 16
Alzhrani, R. M., Alsaab, H. O., Vanamala, K., Bhise, K., Tatiparti, K., Barari, A., Sau, S., & Iyer, A. K. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000262 · Cited by 16
Li, Z., Liu, N., Shah, Z., Jin, L., Tian, L., Sun, X., Zhang, J., Li, Z., Caligiuri, M. A., & Yu, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011890 · Cited by 16
Expression of chosen cell cycle and proliferation markers in pancreatic intraepithelial neoplasia
Dorf, J., Zaręba, K. P., Guzińska-Ustymowicz, K., Kędra, B., Kemonä, A., & Pryczynicz, A. (2018) · Gastroenterology Review · doi:10.5114/pg.2018.75824 · Cited by 15
Misiura, M., Dorf, J., Zaręba, K. P., Kamińska, D., Guzińska-Ustymowicz, K., & Pryczynicz, A. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.11.013 · Cited by 15
Wang, B., Wang, L., Yang, S., & Liu, Z.-J. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1216-4 · Cited by 15
Study human pancreatic cancer in mice: How close are they?
Zhang, Y., Chen, L. L., Yang, J., Fleming, J. B., Chiao, P. J., Logsdon, C. D., & Li, M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.001 · Cited by 16
Izumi, S., Nakamura, S., Mano, S., & Suzuka, I. (2009) · Surgery Today · doi:10.1007/s00595-009-3990-0 · Cited by 15
Tissue microarrays: fast-tracking protein expression at the cellular level
Warford, A. (2004) · Expert Review of Proteomics · doi:10.1586/14789450.1.3.283 · Cited by 15
Byeon, S., du Toit‐Thompson, T., Gillson, J., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2023) · Cancer Medicine · doi:10.1002/cam4.6407 · Cited by 15
Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges
Pian, L.-L., Song, M.-H., Wang, T., Qi, L., Peng, T.-L., & Xie, K.-P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1401829 · Cited by 15
Genetics of Pancreatic Cancer and Its Implications on Therapy
Tatarian, T., & Winter, J. M. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.07.014 · Cited by 14
Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness
Weidemann, S. A., Perez, D. R., Izbicki, J. R., Neipp, M., Mofid, H., Daniels, T., Nahrstedt, U., Jacobsen, F., Bernreuther, C., Simon, R., et al. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1943747 · Cited by 14
Modica, C., Olivero, M., Zuppini, F., Milan, M., Basilico, C., & Vigna, E. (2021) · Cancers · doi:10.3390/cancers13143519 · Cited by 14
The Wnt pathway is active in a small subset of pancreas cancer cell lines
Pujal, J., Capellá, G., & Real, F. X. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.08.002 · Cited by 14
Genetic alterations in precancerous pancreatic lesions and their clinical implications
Turrini, O., Cano, C. E., Legoffic, A., Delpéro, J., Dagorn, J., & Iovanna, J. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.08.007 · Cited by 13
Kotsantis, I., Economopoulou, P., Dritsakos, K., Oikonomopoulos, N., Bakogeorgos, M., Rapti, C., & Kentepozidis, N. K. (2016) · Clinical Case Reports · doi:10.1002/ccr3.737 · Cited by 13
Molecular and Genetic Basis of Pancreatic Carcinogenesis
Bernard, V., Fleming, J. B., & Maitra, A. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2015.11.003 · Cited by 13
Self-citationCurrent topics on precursors to pancreatic cancer.
Takaori, K., Hruban, R. H., Maitra, A., & Tanigawa, N. (2006) · PubMed · Cited by 13
Self-citationMultianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma
Firpo, M. A., Boucher, K. M., Bleicher, J. M., Khanderao, G. D., Rosati, A., Poruk, K. E., Kamal, S., Marzullo, L., Marco, M. D., Falco, A., et al. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00160 · Cited by 12
Das, K. K., Brown, J. W., del-Castillo, C. F., Huynh, T. G., Mills, J. C., Matsuda, Y., Das, K. M., & Mino-Kenudson, M. A. (2021) · Human Pathology · doi:10.1016/j.humpath.2021.01.003 · Cited by 12
Schütte, U., Bisht, S., Brossart, P., & Feldmann, G. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.534453 · Cited by 13
Nanotherapeutics promises for colorectal cancer and pancreatic ductal adenocarcinoma
Bhaw‐Luximon, A., Goonoo, N., & Jhurry, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-42863-7.00006-2 · Cited by 12
Ancillary tests in the diagnosis of liver and pancreatic neoplasms
Misdraji, J., Centeno, B. A., & Pitman, M. B. (2018) · Cancer Cytopathology · doi:10.1002/cncy.22009 · Cited by 12
Weng, C., Lin, Y., & Cheng, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091369 · Cited by 12
Pancreatic Intraepithelial Neoplasia
Hruban, R. H., Brune, K. A., Fukushima, N., & Maitra, A. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_3 · Cited by 12
Self-citationEarly detection markers in Pancreas Cancer
Farrell, J. J., van Rijnsoever, M., & Elsaleh, H. (2005) · Cancer Biomarkers · doi:10.3233/cbm-2005-12-304 · Cited by 12
Tsesmelis, M., Büttner, U. F. G., Gerstenlauer, M., Manfras, U., Tsesmelis, K., Du, Z., Sperb, N., Weissinger, S. E., Möller, P., Barth, T. F. E., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01989-x · Cited by 11
Mottini, C., & Cardone, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145023 · Cited by 11
Sopha, S. C., Gopal, P., Merchant, N. B., Revetta, F. L., Gold, D. V., Washington, K., & Shi, C. (2013) · Europe PMC (PubMed Central) · Cited by 11
Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas
Handra‐Luca, A., Hammel, P. R., Sauvanet, A., Ruszniewski, P. B., & Couvelard, A. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-012-0518-6 · Cited by 11
Chemoprevention of pancreatic cancer—one step closer
Fendrich, V. (2012) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-012-0916-x · Cited by 11
Mesothelin Expression in Pancreatic Mucinous Cysts
Frank, R., Li, S., Ahmad, N. A., Sepulveda, A. R., & Jhala, N. C. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpdttl2i5ecmfg · Cited by 11
PANKRAS II Study Group, Crous‐Bou, M., Porta, M. S., Morales, E., López‐Jiménez, T., Carrato, A., Puigdomènech, E., & Real, F. X. (2008) · Cancer Causes & Control · doi:10.1007/s10552-008-9267-x · Cited by 11
Hashimoto, A., & Hashimoto, S. (2024) · Cancers · doi:10.3390/cancers16234094 · Cited by 11
Bobrowski, A., Spitzner, M., Bethge, S., Müller‐Graf, F., Vollmar, B., & Zechner, D. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.11.016 · Cited by 10
An-liu, W. A. N. G., Liu, H., & Zhang, Y. (2007) · Chinese Medical Journal · doi:10.1097/00029330-200703010-00005 · Cited by 10
The Many Faces of Wnt and Pancreatic Ductal Adenocarcinoma Oncogenesis
Weekes, C. D., & Winn, R. A. (2011) · Cancers · doi:10.3390/cancers3033676 · Cited by 10
Yeh, C., Pang, S., Jung, S., Chen, T.-W., Jan, Y.-Y., & Chen, M. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21604 · Cited by 10
Pancreatic Cancer Genomes: Toward Molecular Subtyping and Novel Approaches to Diagnosis and Therapy
Wood, L. D. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0043-6 · Cited by 10
Lifetime history of alcohol consumption and K‐ras mutations in pancreatic ductal adenocarcinoma
Crous‐Bou, M., Porta, M. S., López‐Jiménez, T., Jariod, M., Malats, N., Morales, E., Guarner, L., Rifà, J., Carrato, A., Real, F. X., et al. (2009) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20483 · Cited by 10
Min, J., Schweizer, L., Zonderland, G., Selvanesan, B. C., Thomsen, J. H., Oldenburg, L., Bae, S.-W., Kim, B., Hernandez, S. D., Jez, G., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1119 · Cited by 9
Self-citationEpigenetic dysregulation in pancreatic cancer: emerging biomarkers and clinical applications
Sultana, H., Solomon, A. D., Wani, A. K., & Shukla, S. K. (2025) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2025.1723159 · Cited by 9
SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas
Handra‐Luca, A., Olschwang, S., & Fléjou, J. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1152-4 · Cited by 9
Komine, R., Kojima, M., Ishii, G., Kudo, M., Sugimoto, M., Kobayashi, S., Takahashi, S., Konishi, M., Kobayashi, T., Akimoto, T., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3809 · Cited by 9
Where and When Does Pancreatic Carcinoma Start?
L�ttges, J., Hahn, S. A., & Kl�ppel, G. (2004) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-004-1028-3 · Cited by 9
Tissue Microarrays for Testing Molecular Biomarkers of Cervical Intraepithelial Neoplasia
Schneider, V. (2006) · Acta Cytologica · doi:10.1159/000325919 · Cited by 9
Sen, S., & Hopwood, V. L. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0171 · Cited by 9
p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
Miller, P., Akama‐Garren, E. H., Owen, R. P., Demetriou, C., Carroll, T. M., Slee, E. A., Moussawi, K. A., Ellis, M., Goldin, R. D., O’Neill, E. E., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01168-3 · Cited by 8
Izumi, S., Nakamura, S., Mano, S., & ONODA, Y. (2013) · Surgery Today · doi:10.1007/s00595-013-0804-1 · Cited by 7
A Minute Pancreatic Ductal Adenocarcinoma with Lipomatous Pseudohypertrophy of the Pancreas
Izumi, S. (2011) · PubMed · doi:10.6092/1590-8577/448 · Cited by 7
The Molecular Pathology of Precursor Lesions of Pancreatic Cancer
Singhi, A. D., & Maitra, A. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_5 · Cited by 7
Self-citationZhu, Y., Wang, J., Wang, F., Yan, Z., Liu, G., Ma, Y., Zhu, W., Li, Y., Xie, L., Bazhin, A. V., et al. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919050122 · Cited by 8
Hu, J., Jiang, J., Xu, B., Li, Y., Wang, B., He, S., Ren, X., Shi, B., Zhang, X., Zheng, H., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117590 · Cited by 6
Izumi, S., Nakamura, S., Mano, S., & Akaki, S. (2014) · Pancreas · doi:10.1097/mpa.0000000000000260 · Cited by 6
Cáceres, M., Quesada, R., Iglesias, M., Real, F. X., Villamonte, M., de Villarreal, J. M., Pérez, M., Andaluz, A., Moll, X., BERJANO, E. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74947-4 · Cited by 6
Hadžija, M. P., Radošević, S., Kovačević, D., Lukač, J., Hadžija, M., Spaventi, R., Pavelić, K., & Kapitanović, S. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2003.12.018 · Cited by 6
Wu, Z., Fu, X., Feng, Y., Zeng, R., Qin, H., & Yao, K. (2025) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2603105 · Cited by 5
Wu, X., Zhu, W., Chen, W., & Ruan, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1806714 · Cited by 5
Griffith, B. D., Kadiyala, P., McGue, J. J., Sun, L., Kumar, A., Espinoza, C. E., Donahue, K. L., Iyer, M. K., Speyer, C. B., Nelson, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0377 · Cited by 5
Inflammation and de-differentiation in pancreatic carcinogenesis
Seimiya, T., Otsuka, M., Iwata, T., Tanaka, E., Suzuki, T., Sekiba, K., Yamagami, M., Ishibashi, R., & Koike, K. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i15.882 · Cited by 5
Molecular diagnostics of hepatobiliary and pancreatic neoplasias
Longerich, T., Stenzinger, A., & Schirmacher, P. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03744-5 · Cited by 5
Sakorafas, G. H., Tsiotos, G. G., Korkolis, D. P., & Smyrniotis, V. E. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2011.12.006 · Cited by 5
Robot-Guided Atomic Force Microscopy for Mechano-Visual Phenotyping of Cancer Specimens
Chen, W., Brandes, Z. R., Roy, R., Chekmareva, M. A., Pandya, H. J., Desai, J. P., & Foran, D. J. (2015) · Microscopy and Microanalysis · doi:10.1017/s1431927615015007 · Cited by 5
S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer
Srivastava, K., Lines, K. E., Jach, D., & Crnogorac‐Jurcevic, T. (2023) · Oncogene · doi:10.1038/s41388-023-02851-y · Cited by 5
Precursor Lesions of Pancreatic Cancer
Matthaei, H., & Maitra, A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6694-0_19 · Cited by 5
Self-citationGenetics of hereditary pancreatic carcinoma
Hahn, S. A., & Bartsch, D. K. (2004) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.07.006 · Cited by 4
Surcel, A., Schiffhauer, E. S., Thomas, D. G., Zhu, Q., DiNapoli, K. T., Herbig, M., Otto, O., Guck, J. R., Jaffee, E. M., Iglesias, P. A., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/190553 · Cited by 4
Zhu, Y., Zhou, S., Yang, F.-Q., Zhang, H., Luo, J., Xie, F., Liu, D., Lei, Y., & Deng, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117046 · Cited by 3
Barreto, S. G. (2018) · Springer eBooks · doi:10.1007/978-981-10-8755-4_16 · Cited by 3
Pancreatic Cancer: Molecular Genetics and Clinical Applications
Sakorafas, G. H., Pappa, I., & Smyrniotis, V. E. (2010) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0006057.pub2 · Cited by 3
Genetics of Hereditary Pancreatic Carcinoma
Hahn, S. A., & Bartsch, D. K. (2005) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.12.008 · Cited by 3
Does biology determine survival in pancreatic cancer?
Barreto, S. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0706 · Cited by 3
Zhang, X., Wong, W., Cho, H. S., Yang, D., Dixon, G., Luo, R., Liu, D., Torre, D., Umeda, S., Gonzãlez, F., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.04.012 · Cited by 2
Self-citationHarnessing the potential of CAR-NK cell therapy in gastrointestinal cancers: From bench to bedside
Vanan, A. G., Askari, M. R., Bagheri, K., Arghand, M. R., Ghorbaninezhad, F., Tahmasebi, S., Taghizadeh-Anvar, M., Nouri, S., & Safarzadeh, E. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118380 · Cited by 2
Metadata
- Authors
- Maitra, A., Adsay, N. V., Argani, P., Iacobuzio-Donahue, C., De Marzo, A., Cameron, J. L., Yeo, C. J., & Hruban, R. H.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Maitra, Anirban
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 16
- Issue
- 9
- Pages
- 902-912
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W1980447806
- Cited by
- 429
- References
- 95
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 13 · 2023: 18 · 2022: 11 · 2021: 16 · 2020: 11 · 2019: 14 · 2018: 24 · 2017: 16 · 2016: 13 · 2015: 16 · 2014: 22 · 2013: 19 · 2012: 24
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Modern Pathology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P50CA-62924, P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, tumor progression, precursor lesions, tissue microarray, molecular pathogenesis, p53, β-catenin, p16, cyclin D1, Ki-67, TOP2A, MUC1, MUC2, mesothelin, prostate stem cell antigen, fascin, 14-3-3 sigma, early detection
- MeSH terms
- Adenocarcinoma, Carcinoma in Situ, DNA, Neoplasm, Humans, Immunohistochemistry, Pancreatic Neoplasms, Precancerous Conditions, Biomarkers, Tumor, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review